Autopsy report · NCT00276744
Individualized Drug Treatment for Treating Patients With Pancreatic Cancer
Cause of deathOther
“Because there was no longer an active laboratory component to this study.”
Life of this trial
- Registered 3 months after it had already started.
- Ran for about 4 years 6 months before it stopped.
- 249 participants enrolled.
- Results were posted on the registry 8 years 4 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Sponsor type
- University, hospital or other
- Conditions
- Pancreatic Cancer
- Interventions
- cetuximab; capecitabine; docetaxel; Erlotinib; Gemcitabine; Irinotecan
- Participants
- 249
- Sites
- 1
- Countries
- United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.